Silence Therapeutics plc
SLN
Rank in Stocks
#8993
Silence Therapeutics plc is a London, UK-based biotechnology company... Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
Share Price
$19.75
Last synced: 2026-11-09
Market Cap
$932.87M
Change (1 day)
0.10%
Change (1 year)
185.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Silence Therapeutics plc (SLN)
Category
Healthcare
Operating Margin for Silence Therapeutics plc (SLN)
Operating Margin as of November 2026 TTM: -10,880.25%
According to Silence Therapeutics plc's latest financial reports, its current operating margin (TTM) is -10,880.25%. At the end of 2025 the company had an operating margin of -16,055.99%.
Operating Margin history for Silence Therapeutics plc from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -10,880.25% | -32.24% |
| 2025 | -16,055.99% | 10,868.70% |
| 2024 | -146.38% | -25.12% |
| 2023 | -195.48% | -30.65% |
| 2022 | -281.87% | -23.62% |
| 2021 | -369.02% | -43.60% |
| 2020 | -654.26% | -92.98% |
| 2019 | -9,317.21% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2017 | -89,943.75% | 5,716.97% |
| 2016 | -1,546.23% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | -80,846.67% | 942.66% |
| 2013 | -7,753.85% | -51.97% |
| 2012 | -16,143.56% | 1,836.33% |
| 2011 | -833.72% | 127.84% |
| 2010 | -365.93% | -16.53% |
| 2009 | -438.42% | 24.29% |
| 2008 | -352.74% | 146.64% |
| 2007 | -143.02% | -34.76% |
| 2006 | -219.21% | -71.38% |
| 2005 | -765.82% | -63.85% |
| 2004 | -2,118.24% | 965.08% |
| 2003 | -198.88% | 14.17% |
| 2002 | -174.20% | -92.06% |
| 2001 | -2,193.48% | 669.13% |
| 2000 | -285.19% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.00% |
US
|
|
| -149.01% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
|
| 29.35% | -100.00% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Silence Therapeutics plc's operating margin
What is Silence Therapeutics plc's operating margin?
Silence Therapeutics plc's operating margin is -10,880.25%, as of Nov 2026.
What was Silence Therapeutics plc's operating margin in 2025?
In 2025, Silence Therapeutics plc's operating margin was -16,055.99%, compared with -146.38% in 2024.
How has Silence Therapeutics plc's operating margin changed since 2020?
From 2020 to 2025, Silence Therapeutics plc's operating margin was highest in 2024 (-146.38%) and lowest in 2025 (-16,055.99%).
How does Silence Therapeutics plc's operating margin compare with similar companies?
Silence Therapeutics plc's operating margin (-10,880.25%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.